Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by TopBrokeron Nov 02, 2021 1:46pm
248 Views
Post# 34078266

Shareholders Beware

Shareholders BewareGlass Lewis was paid to say they recommend a consolidation. Lets look at this Boards track record, first they said partnering deals are close and they are in discussions, that was over a year ago, lie number one. Then they said the IND for PMN 310 would be complete in 2020, lie number two. Then they said they listen to shareholders and would not dilute the stock for unnecessary purposes, lie number three, they gave themselves huge wages. Then when shareholders were so disgusted with Goldstein he said he would leave the Company, now Gene places him as President, lie number four. Now the biggest lie of them all a consolidation of 30 to 60 to one and we are supposed to trust these people. They do everything for themselves and do not give a dam about shareholders. I recommend saying NO to a huge consolidation and ask them what have they done to increase shareholder value since they came to this Company, NOTHING.
<< Previous
Bullboard Posts
Next >>